Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. MASH is the updated term for ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...